• Anchor:  Phase lll Randomized, Double Masked Trial of the Efficacy of rhuFab V2 in Subjects with  Classic Neovascular Macular Degeneration.
  • Marina:   Phase lll Randomized, Double Masked Trial of the Efficacy of rhuFab V2 in Subjects with Minimally Classic or Occult Subfoveal Neovascular  Macular Degeneration.
  • Sailor: A phase lllB study to evaluate the safety and efficacy of intravitreal ranibizumab in a large population of subjects with neovascular age-related macular degeneration (AMD).
  • Ohr Pharmaceutical, Inc. Protocol OHR-1601:  A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration
  • The astemizole retinopathy trial: The effect of astemizole on non-clinically significant diabetic macular edema.
  • The vitrectomy for macular hole study(VMHS): A randomized, multicenter clinical trial that compared vitrectomy surgery to observation for eyes with stage 3 or 4 macular holes.
  • Corneal toxicity of belantamab mafodotin in patients treated for multiple myeloma.
  • Study Protocol J1I-MC-GZBOA: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Decline in Kidney Function in Participants with Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease.
  • Ohr Pharmaceutical, Inc. Protocol OHR-1601:  A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration
  • Eli, Lilly and Company.  A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index >/= 27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease